Volume 31, Number 12—December 2025
CME ACTIVITY - Research
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016–2020
Table 4
TB treatment outcomes in the microbiologically eligible population of the TB treatment-shortening trial, Tuberculosis Trials Consortium Study 31/AIDS Clinical Trials Group A5349, January 2016–July 2020*
| Outcome | Pregnancies with exposure to study drugs, N = 29 |
Pregnancies without exposure to study drugs, N = 67 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Control, n = 13 | RPT/MOX, n = 9 | RPT, n = 7 | Total, N = 29 | Control, n = 22 | RPT/MOX, n = 24 | RPT, n = 21 | Total, N = 67 | ||
| Favorable, total† |
6 (46.2) |
5 (55.6) |
4 (57.1) |
15 (51.7) |
21 (95.5) |
23 (95.8) |
19 (90.5) |
63 (94.0) |
|
| Not favorable, total‡ | 7 (53.8) | 4 (44.4) | 3 (42.9) | 14 (48.3) | 1 (4.5) | 1 (4.2) | 2 (9.5) | 4 (6.0) | |
| Unfavorable outcome, total | 0 | 0 | 0 | 0 | 1 (4.5) | 0 | 1 (4.8) | 2 (3.0) | |
| TB-related unfavorable outcome, total | 0 | 0 | 0 | 0 | 1 (4.5) | 0 | 0 | 1 (1.5) | |
| Not seen at month 12; last culture positive | 0 | 0 | 0 | 0 | 1 (4.5) | 0 | 0 | 1 (1.5) | |
| Not TB-related unfavorable outcome, total | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (1.5) | |
| Treatment changed because of adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (1.5) | |
| Not assessable outcome, total | 7 (53.8) | 4 (44.4) | 3 (42.9) | 14 (48.3) | 0 | 1 (4.2) | 1 (4.8) | 2 (3.0) | |
| Not seen at month 12; last culture negative | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (1.5) | |
| Withdrawn from treatment because of pregnancy | 7 (53.8) | 4 (44.4) | 3 (42.9) | 14 (48.3) | 0 | 1 (4.2) | 0 | 1 (1.5) | |
*Values are no. (%). Microbiologically eligible analysis population included the subset of all enrolled participants who receive a treatment assignment who, in addition, have culture confirmation of drug-susceptible TB at study entry. MOX, moxifloxacin; RPT, rifapentine; TB, tuberculosis. †All participants with favorable outcome had culture-negative status at month 12. ‡Participants with unfavorable and not assessable outcomes were considered to have a not favorable outcome.
1Members of this group are listed at the end of this article.
2Members of this group are listed at the end of this article.